MX2007007033A - Estreptococus del grupo b. - Google Patents

Estreptococus del grupo b.

Info

Publication number
MX2007007033A
MX2007007033A MX2007007033A MX2007007033A MX2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A
Authority
MX
Mexico
Prior art keywords
streptococcus
group
vaccines
antibiotics
polypeptides
Prior art date
Application number
MX2007007033A
Other languages
English (en)
Spanish (es)
Inventor
Vega Masignani
Herve Tettelin
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of MX2007007033A publication Critical patent/MX2007007033A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007007033A 2004-12-22 2005-12-21 Estreptococus del grupo b. MX2007007033A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63894304P 2004-12-22 2004-12-22
US64043804P 2004-12-30 2004-12-30
PCT/US2005/046491 WO2006069200A2 (en) 2004-12-22 2005-12-21 Group b streptococcus

Publications (1)

Publication Number Publication Date
MX2007007033A true MX2007007033A (es) 2007-08-03

Family

ID=36602309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007033A MX2007007033A (es) 2004-12-22 2005-12-21 Estreptococus del grupo b.

Country Status (8)

Country Link
US (1) US20090104218A1 (enExample)
EP (1) EP1828231A2 (enExample)
JP (1) JP2008525033A (enExample)
AU (1) AU2005319174A1 (enExample)
CA (1) CA2591510A1 (enExample)
IL (1) IL183830A0 (enExample)
MX (1) MX2007007033A (enExample)
WO (1) WO2006069200A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
NZ512297A (en) 1998-12-22 2003-12-19 Microscience Ltd Genes and proteins of group a strep, and their use
WO2002034771A2 (en) 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
EP1801235A1 (en) 2005-12-20 2007-06-27 Institut Pasteur Rapid detection of the "high virulent" ST-17 clone of Group B streptococcus
CA2654968A1 (en) * 2006-06-19 2008-02-21 Mutabilis Identification of genes implicated in the virulence of streptococcus agalactiae
WO2009027768A2 (en) * 2006-07-26 2009-03-05 Novartis Ag Immunogenic compositions for gram positive bacteria
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
EP2135877A1 (en) * 2008-06-19 2009-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Marker of steptococcus anginosus/Streptococcus constellatus (Moac) and uses thereof
US8147849B2 (en) 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
NZ597858A (en) 2009-06-29 2014-01-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CN103501809B (zh) 2011-01-20 2018-08-10 健诺西生物科学公司 针对肺炎链球菌(Streptococcus Pneumoniae)的疫苗和组合物
EP2682401A4 (en) * 2011-02-02 2015-06-03 Microbial Chem Res Found FOR OBTAINING THE BLOOD-BRAIN-DISABLED MEDICAMENT OUTPUT MATERIAL, PEPTIDE THEREOF AND USE THEREOF
EP2557424A1 (en) 2011-08-11 2013-02-13 InGen Biosciences Method for diagnosing Streptococcus, Enterococcus and Pepstostreptococcus genera infections
CN104321335A (zh) * 2012-02-24 2015-01-28 诺华股份有限公司 菌毛蛋白质和组合物
EP2831250B1 (en) * 2012-03-30 2021-11-24 DuPont US Holding, LLC Enzymes useful for peracid production
KR20150073943A (ko) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
WO2015008214A1 (en) * 2013-07-16 2015-01-22 Universite De Lausanne Bacterial lysins and uses thereof
BR112017002183A2 (pt) * 2014-08-05 2018-01-16 Glaxosmithkline Biologicals S.A. conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero
AU2017214441B2 (en) 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases
US11028159B2 (en) 2017-05-02 2021-06-08 Venomyx, Inc. Composition and methods for treating snake envenomation
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
PL239045B1 (pl) * 2018-01-09 2021-11-02 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Epitop specyficzny dla zakaźnych Streptococcus agalactiae oraz sposób wykrywania zakażenia pacjenta szczepem Streptococcus agalactiae
AU2019286648B2 (en) * 2018-06-13 2023-11-23 Gen-Probe Incorporated Compositions and methods for detecting group B Streptococcus nucleic acid
CA3172359A1 (en) 2018-08-06 2020-02-13 Medikine, Inc. Il-2 receptor binding compounds
US11718654B2 (en) 2019-11-05 2023-08-08 Medikine, Inc. IL-2R-βγ binding compounds
IL293553A (en) * 2019-12-06 2022-08-01 Theratechnologies Inc Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
AU2021219847A1 (en) * 2020-02-12 2022-10-13 Massachusetts Institute Of Technology Field deployable CRISPR-Cas diagnostics and methods of use thereof
US11453907B2 (en) 2020-03-23 2022-09-27 The Broad Institute, Inc. Crispr effector system based coronavirus diagnostics
WO2022026534A1 (en) * 2020-07-28 2022-02-03 Kansas State University Research Foundation Sars-cov-2 immunogenic compositions and methods for protecting against sars-cov-2 clinical signs
IL302575A (en) * 2020-11-04 2023-07-01 Medikine Inc IL-2R BETA GAMMA c BINDING COMPOUNDS AND USES THEREOF
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2025017062A1 (en) * 2023-07-18 2025-01-23 Intervet International B.V. New type of streptococcus agalactiae serotype ia bacterium and vaccines thereof
WO2025151408A1 (en) * 2024-01-08 2025-07-17 Denali Therapeutics Inc. Compositions and methods for modulating tau expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
GB9808327D0 (en) * 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
JP2002531054A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド B群連鎖球菌由来の核酸およびタンパク質
GB9921125D0 (en) * 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
FR2824074A1 (fr) * 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
JP5116971B2 (ja) * 2002-10-15 2013-01-09 インターセル アーゲー B群連鎖球菌の接着因子をコードする核酸、b群連鎖球菌の接着因子、およびその使用
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Also Published As

Publication number Publication date
EP1828231A2 (en) 2007-09-05
JP2008525033A (ja) 2008-07-17
WO2006069200A3 (en) 2007-03-01
AU2005319174A1 (en) 2006-06-29
CA2591510A1 (en) 2006-06-29
WO2006069200A2 (en) 2006-06-29
IL183830A0 (en) 2007-10-31
US20090104218A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
MX2007007033A (es) Estreptococus del grupo b.
MY154904A (en) Neuropilin antagonists
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
EA201301072A1 (ru) Антитела против il-23p19 и их применение
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
AU2013201592A1 (en) Improved vaccines and methods for using the same
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
IL184288A0 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
WO2008002672A3 (en) Targets for use in diagnosis, prognosis and therapy of cancer
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
PL2038294T3 (pl) 18-metylo-19-norandrost-4-eno-17,17-spiroetery (18-metylo-19-nor-20-spiroks-4-en-3-ony), jak również preparaty farmaceutyczne zawierające te związki
WO2007117763A3 (en) Methods and compositions for targeting relt
WO2009050277A3 (en) Edta resistant s100a12 complexes (erac)
WO2008054595A3 (en) Drug controlled molecular tags
WO2003093298A3 (en) Immunogenic peptides
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
TW200640932A (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
GB0818080D0 (en) Immunogenic peptides
WO2010110931A3 (en) Glycoconjugate vaccines
WO2007102946A3 (en) Crystalline polypeptides
WO2006089209A3 (en) Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
WO2007077464A3 (en) Chicken virus vaccine and diagnostic
SI1951738T1 (sl) Nadaljnje kristalinične oblike rostafuroksina

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: J. CRAIG VENTER INSTITUTE, INC.

FA Abandonment or withdrawal